In order to create the best conditions for success in preparative chromatography, the company's operations are focused on Chromatography and the Drug Development operations are down-prioritized and placed in subsidiaries for future opportunities. The management team is adapted to reflect this and CSO Gary Pitcairn and VP Drug Development Ulf Ericsson will leave the company for new opportunities.
 
" Our work within Drug Development has reached a point where continued development is very resource-intensive and we have therefore decided to currently focus the company's business primarily on Chromatography. Our potential in chromatography is very large and we see a great interest in our products, as well as a need for additional suppliers of the type of high-quality silica that we produce. Focusing mainly on chromatography facilitates reaching positive cash flow for the company faster", Nanologica's CEO Andreas Bhagwani comments.
 
”We finally have a product within preparative chromatography that we are satisfied with and we will shortly start the first deliveries to customers. We are determined to achieve a commercial breakthrough during this year and are now optimizing our resources to achieve that”, Andreas Bhagwani continues.
 
Following the change, Nanologica's management team consists of CEO Andreas Bhagwani, CFO Eva Osterman, COO Anna-Karin Renström, and SVP Chromatography Katarina Alenäs.

”I would also like to take this opportunity to thank the drug development team for their efforts in the development of the inhalation platform”, Andreas Bhagwani concludes.